Loading...
Loading...
Guggenheim Securities downgraded
Aegerion Pharmaceuticals, Inc.AEGR from Neutral to Sell.
Aegerion Pharmaceuticals shares have dropped 39.92 percent over the past 52 weeks, while the S&P 500 index has surged 5.01 percent in the same period.
Aegerion Pharmaceuticals' shares fell 2.47 percent to $18.13 in pre-market trading.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in